Friday, September 25, 2026

Roche to propose Christophe Weber for Board election

The Board of Directors of Roche Holding Ltd plans to nominate Dr. Christophe Weber for election to the company’s Board. The vote is scheduled for the Annual General Meeting on 9 March 2027.

Weber previously served as CEO of Takeda Pharmaceuticals. Roche cited his healthcare industry expertise and leadership background in connection with the planned nomination.

Board expertise in focus

Roche Chairman Severin Schwan welcomed the proposed candidacy. According to the company, Weber’s industry knowledge is expected to add further strength to the Board’s work.

The final decision rests with shareholders, who will vote on the election at the Annual General Meeting.

About Roche

Roche is a global healthcare company active in diagnostics, pharmaceuticals and digital solutions. Founded in Basel in 1896, the company operates in more than 150 countries.

Its areas of focus include oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology. Genentech is wholly owned by the Roche Group, and Roche is the majority shareholder of Japan-based Chugai Pharmaceutical.